NCT02243917 - A Phase 1 Study Evaluating CB-5083 in Subjects With Advanced Solid Tumors | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

October 11, 2014

Primary Completion Date

August 25, 2017

Study Completion Date

August 25, 2017

Conditions

Advanced Solid Tumors

Interventions

DRUG

CB-5083

Trial Locations (6)

University of Pennsylvania, Abramson Cancer Center, Philadelphia

Winship Cancer Institute of Emory University, Atlanta

University of Colorado, Aurora

HonorHealth Research Institute, Scottsdale

Cedars-Sinai Medical Center, Samuel Oschin Comprehensive Cancer Institute, Los Angeles

University of California San Francisco, San Francisco